Salarius Pharmaceuticals Stock Performance
| SLRX Stock | USD 0.93 0.05 5.68% |
The entity has a beta of 0.87, which indicates possible diversification benefits within a given portfolio. Salarius Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Salarius Pharmaceuticals is expected to follow. At this point, Salarius Pharmaceuticals has a negative expected return of -2.25%. Please make sure to validate Salarius Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Salarius Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Salarius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 5.9 M | |
| Free Cash Flow | -4.5 M |
Salarius Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 576.00 in Salarius Pharmaceuticals on August 29, 2025 and sell it today you would lose (483.00) from holding Salarius Pharmaceuticals or give up 83.85% of portfolio value over 90 days. Salarius Pharmaceuticals is currently does not generate positive expected returns and assumes 10.0023% risk (volatility on return distribution) over the 90 days horizon. In different words, 89% of stocks are less volatile than Salarius, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Salarius Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Salarius Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Salarius Pharmaceuticals, and traders can use it to determine the average amount a Salarius Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2248
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLRX |
Estimated Market Risk
| 10.0 actual daily | 89 89% of assets are less volatile |
Expected Return
| -2.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Salarius Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Salarius Pharmaceuticals by adding Salarius Pharmaceuticals to a well-diversified portfolio.
Salarius Pharmaceuticals Fundamentals Growth
Salarius Stock prices reflect investors' perceptions of the future prospects and financial health of Salarius Pharmaceuticals, and Salarius Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Salarius Stock performance.
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 3.49 M | ||||
| Shares Outstanding | 5.86 M | ||||
| Price To Book | 1.22 X | ||||
| Price To Sales | 18.12 X | ||||
| EBITDA | (5.73 M) | ||||
| Cash And Equivalents | 22.65 M | ||||
| Cash Per Share | 10.09 X | ||||
| Total Debt | 221.87 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 4.50 X | ||||
| Cash Flow From Operations | (4.53 M) | ||||
| Earnings Per Share | (24.24) X | ||||
| Total Asset | 3.02 M | ||||
| Retained Earnings | (81.92 M) | ||||
| Current Liabilities | 1.97 M | ||||
About Salarius Pharmaceuticals Performance
Evaluating Salarius Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Salarius Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Salarius Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Things to note about Salarius Pharmaceuticals performance evaluation
Checking the ongoing alerts about Salarius Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Salarius Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Salarius Pharmaceuticals generated a negative expected return over the last 90 days | |
| Salarius Pharmaceuticals has high historical volatility and very poor performance | |
| Salarius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Salarius Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.58 M) with loss before overhead, payroll, taxes, and interest of (15.84 M). | |
| Salarius Pharmaceuticals currently holds about 22.65 M in cash with (4.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Salarius Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Whats Driving the Market Sentiment Around Dicks Sporting Goods Inc |
- Analyzing Salarius Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Salarius Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Salarius Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Salarius Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Salarius Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Salarius Pharmaceuticals' stock. These opinions can provide insight into Salarius Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.